Nefazan® 75 mg

Clopidogrel 75 mg | Antiplatelet Therapy

Nefazan® contains clopidogrel 75 mg, an oral antiplatelet agent belonging to the P2Y12 receptor inhibitor class. It works by irreversibly inhibiting ADP-mediated platelet activation and aggregation, helping prevent atherothrombotic events.

Therapeutic Indications

Nefazan® is indicated for the prevention of atherothrombotic events in adult patients with:

• Recent myocardial infarction

• Recent ischemic stroke

• Established peripheral arterial disease

• Acute coronary syndrome, including selected patients undergoing percutaneous coronary intervention (PCI), in combination with aspirin

Nefazan® is also indicated in combination with aspirin for selected patients with atrial fibrillation who are unsuitable for vitamin K antagonist therapy, according to the approved prescribing information.

Dosage and Administration

The usual maintenance dose is one 75 mg tablet once daily, with or without food. Loading doses and treatment combinations depend on the clinical indication and physician's prescription.

Product Information

• Active ingredient: Clopidogrel 75 mg (as clopidogrel bisulfate)

• Pharmaceutical form: Film-coated tablets

• Pack size: 30 tablets

• Manufacturer: Laboratorio Elea Phoenix S.A., Argentina

• Distributor in Lebanon: Droguerie Phenicia

• Storage: Below 30°C

• Dispensing status: Prescription only

Important Safety Information

Nefazan® is contraindicated in patients with active pathological bleeding, severe hepatic impairment, or hypersensitivity to its components. Bleeding is an important potential adverse effect. Concomitant use with medications that increase bleeding risk requires medical assessment. The use of omeprazole or esomeprazole alongside clopidogrel should generally be avoided because of potential drug interactions.

For complete indications, contraindications, warnings, and precautions, consult the full Patient Information Leaflet in teh attached PDF